Oregon State University: FDA approving drugs after fewer trials, providing less information to public, OSU studies find

Oregon State University: FDA approving drugs after fewer trials, providing less information to public, OSU studies find. “The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found. Researchers agree it is important to minimize delays in making treatments for diseases such as cancer available to patients, but they say their findings point to a need for greater transparency around how drugs receive approval.”